Compare Godaddy Inc (GDDY) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Gilead Sciences, Inc. — how do they compare? Godaddy Inc trades at $104.38 (market cap $13.07B), while Gilead Sciences, Inc. trades at $148.68 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 14× Godaddy Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Godaddy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 65 Days and Gilead Sciences, Inc. for 111 Days on average.
| GDDY | GILD | |
|---|---|---|
Market Cap | $13.07B | $182.40B |
Volume | 1,831,274 | 4,469,821 |
Sector | Technology | Health |
52-Week High | $135.18 | $155.80 |
52-Week Low | $75.07 | $116.74 |
Typical Hold Time | 65 Days | 111 Days |
Enterprise Value | $15.75B | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $97.21, down 0.99% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company shows strong profitability with 63.8% gross margins and has beaten earnings estimates for three consecutive quarters. Revenue growth continues steadily from $4.95B in 2025 to projected $5.1B in 2026. Analyst consensus remains positive with 57.9% buy ratings and a $96.20 price target, though the stock faces headwinds from multiple securities class action lawsuits alleging misleading disclosures about domain pricing strategies.
The outlook remains cautiously optimistic given strong fundamentals and earnings momentum, but legal risks from ongoing securities litigation present significant near-term uncertainty. Investors should weigh the company's solid operational performance against potential legal liabilities and stock price volatility stemming from the class action proceedings with October 2026 deadlines.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
